Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

LEMBOREXANT vs LENVATINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

LEMBOREXANT vs LENVATINIB: Safety Overview

Metric LEMBOREXANT LENVATINIB
Total FAERS Reports 989 33,766
Deaths Reported 44 4,449
Death Rate 4.4% 13.2%
Hospitalizations 278 19,975
Average Patient Age 58.9 yrs 65.4 yrs
% Female Patients 63.4% 55.8%
FDA Approval Date Apr 7, 2020 Feb 13, 2015
Manufacturer Eisai Inc. Eisai Inc.
Route ORAL ORAL
Marketing Status Prescription Prescription